The results showed that RUNX3 (p<0.001) with an AUC of 0.77 (SE=0.055; 95% CI: 0.664–0.879), sensitivity of 0.59, and specificity of 0.95, and RPRM (p<0.001) with an AUC of 0.70 (SE=0.059; 95% CI: 0.586–0.816), sensitivity of 0.47, and specificity of 0.93 could discriminate the early-stages GC patients from the normal controls with the highest performances (Table 2). This evidence concerns the gene RUNX3 and gastric cancer.